The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for metastatic pancreatic cancer.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/6/2022 | $3.00 | Buy | Maxim Group |
Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter 2024. Conference Call & Webcast Date: Tuesday, November 12, 2024Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 5
Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 million provides runway through key milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, Aug. 1, 2024 /PRNewswire/ -- Oncolytics B
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024. Conference Call & WebcastDate: Thursday, August 1, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In – International: (646) 357-8785RapidConnect: to join the conference call without operator assi
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equi
SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board"). "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics. As we begin preparations to initiate piv
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced the appointment of Jonathan Rigby to its Board of Directors. "Jonathan has successfully built, financed, listed, and led several life science companies across a range of therapeutic areas, and I am thrilled to welcome him to our Board," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "His extensive executive leadership experience, together with his business development and co
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Nov. 14, 2024 /PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American Medical Association is pointing out the alarming trend of rising cancer rates, especially with younger people. According to data released from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), a map shared by Newsweek showed that the prevalence of cancer varies significantly from state to state. Thankfully, there are plenty of new breakthroughs in the fight against cancer that the World Eco
BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.6 million as of September 30, 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 12, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial resul
Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter 2024. Conference Call & Webcast Date: Tuesday, November 12, 2024Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 5
Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00
H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy.
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO during Dr. Coffey's absence. "On behalf of the Board, I would like to wish Matt a swift recovery. In the interim, the Board and I are highly confident in our tenured executive team's ability to continue executing our mission, achieve our strategic priorities, and drive forward our registration-enabling clinical plans for pela
SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety. It is supported by the US$5M Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award, an innovative program established to accelerate the development of n